VYNE Therapeutics Past Earnings Performance
Past criteria checks 0/6
VYNE Therapeutics has been growing earnings at an average annual rate of 40.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 48.6% per year.
Key information
40.8%
Earnings growth rate
68.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -48.6% |
| Return on equity | -53.4% |
| Net Margin | -6,915.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
Oct 09
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10Revenue & Expenses Breakdown
How VYNE Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -34 | 14 | 24 |
| 30 Jun 24 | 0 | -28 | 14 | 17 |
| 31 Mar 24 | 0 | -29 | 14 | 17 |
| 31 Dec 23 | 0 | -28 | 13 | 16 |
| 30 Sep 23 | 0 | -29 | 13 | 18 |
| 30 Jun 23 | 0 | -33 | 14 | 20 |
| 31 Mar 23 | 0 | -31 | 15 | 17 |
| 31 Dec 22 | 0 | -34 | 16 | 18 |
| 30 Sep 22 | 1 | -35 | 17 | 18 |
| 30 Jun 22 | 1 | -40 | 19 | 19 |
| 31 Mar 22 | 1 | -42 | 19 | 20 |
| 31 Dec 21 | 1 | -44 | 20 | 20 |
| 30 Sep 21 | 5 | -59 | 33 | 23 |
| 30 Jun 21 | 8 | -69 | 48 | 24 |
| 31 Mar 21 | 19 | -226 | 70 | 32 |
| 31 Dec 20 | 21 | -256 | 90 | 44 |
| 30 Sep 20 | 17 | -270 | 94 | 51 |
| 30 Jun 20 | 14 | -269 | 85 | 57 |
| 31 Mar 20 | 2 | -120 | 65 | 56 |
| 31 Dec 19 | 0 | -95 | 45 | 51 |
| 30 Sep 19 | 1 | -71 | 27 | 48 |
| 30 Jun 19 | 2 | -64 | 19 | 48 |
| 31 Mar 19 | 3 | -63 | 16 | 52 |
| 31 Dec 18 | 4 | -74 | 14 | 64 |
| 30 Sep 18 | 4 | -77 | 12 | 69 |
| 30 Jun 18 | 4 | -80 | 12 | 71 |
| 31 Mar 18 | 4 | -77 | 12 | 68 |
| 31 Dec 17 | 4 | -66 | 11 | 58 |
| 30 Sep 17 | 4 | -59 | 13 | 52 |
| 30 Jun 17 | 6 | -47 | 12 | 42 |
| 31 Mar 17 | 6 | -39 | 10 | 35 |
| 31 Dec 16 | 6 | -29 | 9 | 26 |
| 30 Sep 16 | 4 | -24 | 8 | 20 |
| 30 Jun 16 | 2 | -21 | 7 | 16 |
| 31 Mar 16 | 1 | -18 | 7 | 12 |
| 31 Dec 15 | 1 | -17 | 7 | 11 |
| 30 Sep 15 | 4 | -11 | 6 | 9 |
| 30 Jun 15 | 4 | -16 | 5 | 8 |
| 31 Mar 15 | 4 | -15 | 4 | 5 |
| 31 Dec 14 | 5 | -11 | 3 | 4 |
| 30 Sep 14 | 3 | -12 | 2 | 2 |
| 30 Jun 14 | 3 | -4 | 1 | 1 |
| 31 Mar 14 | 3 | -2 | 1 | 1 |
| 31 Dec 13 | 1 | -2 | 1 | 1 |
Quality Earnings: VYNE is currently unprofitable.
Growing Profit Margin: VYNE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VYNE is unprofitable, but has reduced losses over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare VYNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VYNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: VYNE has a negative Return on Equity (-53.43%), as it is currently unprofitable.